wherein R_1 is selected from the group consisting of alkyl of 1 to 6 carbon atoms, alkenyl and alkynyl of 2 to 6 carbon atoms haloalkyl of 1 to 6 carbon atoms, alkoxy alkyl of 2 to 12 carbon atoms and alkylthioalkyl of 2 to 12 carbon atoms, R_p is hydrogen or an easily cleavable group, R_{18} and R_{19} are individually selected from the group consisting of hydrogen, halogen, OH and alkyl and alkoxy of 1 to 6 carbon atoms and its non-toxic, pharmaceutically acceptable salts.

REMARKS

Reconsideration of this application is requested in view of the amendments to the claims and the remarks presented herein.

The claims in the application are claims 5 to 8 and 18 to 24. Claims 5 to 8 and 24 stand allowed.

Claims 18 to 23 stand rejected under 35 USC 112 as being indefinite in the expression "unsubstituted or substituted camptothecin analog".

Applicants respectfully traverse this ground of rejection since the amended claims are believed to properly define the invention so as to comply with 35 USC 112. Claim 18 has been amended to cancel the term "analog" which was intended in the last amendment but was inadvertently not deleted. Also, claim 18 has